Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan.

ABSTRACT:

Background

Lenvatinib was approved for use in unresectable hepatocellular carcinoma (uHCC) in Japan in 2018. Patients with diverse clinical characteristics receive lenvatinib treatment in clinical practice. Thus, it is crucial to evaluate the safety and effectiveness of lenvatinib in real-world clinical settings.

Objective

This study aimed to evaluate the real-world safety and effectiveness of lenvatinib for uHCC in clinical practice in Japan.

Patients and methods

Between July 2018 and January 2019, patients with uHCC who were administered lenvatinib for the first time were enrolled in this prospective, multicenter, observational post-marketing study (NCT03663114). Patients were orally administered lenvatinib and followed up for 12 months. For safety, adverse drug rea

SUBMITTER: Furuse J 

PROVIDER: S-EPMC10232401 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature